CanaQuest and Neeka Health Partner to Conduct Clinical Studies With Mentanine

Seeking AlphaApr 25, 2023 09:56 ET

CBD Combined With Essential Fatty Acids Is 40% More Efficient In Epilepsy Seizure Reduction Than Regular CBD, New Study

CANAQUEST MEDICAL CORP (OTCPK:CANQF), a clinical-stage life sciences company focused on drug discovery and development of next-generation targeted cannabinoid therapeutics for the central nervous syst

Benzinga Real-time NewsDec 9, 2022 07:58 ET

CanaQuest Achieves Statistically Significant Reduction of Seizures for Epilepsy Compared to Standard CBD

Drug Candidate, CQ-001 (cannabidiol "CBD" + IP formula), also demonstrated substantially reduced seizures at higher doses, with less CBD, compared to standard CBD.TORONTO, ON / ACCESSWIRE / December 8

AccesswireDec 8, 2022 11:20 ET

Canaquest Launches Mentanine (R) (Cannabidiol + IP Formula) in the US via WWW.CANAQUESTSTORE.COM, Supported by Western University Pre-Clinical Trials Targeting Anxiety, Depression and PTSD

USERS REPORT INCREASED MENTAL CLARITY,BETTER SLEEP, MORE ENERGY, AND LESS BRAIN FOG AND JOINT STIFFNESSTORONTO, ON / ACCESSWIRE / September 8, 2022 / CANAQUEST MEDICAL CORP (OTC PINK:CANQF) (the "Comp

AccesswireSep 8, 2022 09:05 ET